dacarbazine,doxorubicin,brentuximab vedotin,vinblastine,bleomycin,vincristine
seagen
['lymphoma', 'hodgkin']
outstanding 94.9% (!!) 3-year progression free survival for brecadd in advanced stage classical hodgkin lymphoma from the ghsg hd21 rct of 1500 patients! wow! #17icml 
haematology registrar | @harvardmed fellow @PORTAL_research | evidence-based medicine & policy | lymphoma | myeloma | Fulbright | writer | SoMe Ed @BrJHaem